SCHEMBL4255290

SCHEMBL4255290

COc1cc(C2C(C#N)=C(N)Oc3cc(C)n(C)c(=O)c32)cc(Br)c1OC(C)=O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.59
KDM4E B2RXH2 7/20 0.59
KMT2A Q03164 3/20 0.59
LMNA P02545 3/20 0.56
RAB9A P51151 1/20 0.56
GAA P10253 2/20 0.50
HTT P42858 2/20 0.50
MAPT P10636 1/20 0.49
HSD17B10 Q99714 4/20 0.48
HPGD P15428 3/20 0.48
CASP1 P29466 3/20 0.48
CASP7 P55210 3/20 0.48
ALOX15 P16050 2/20 0.48
GLA P06280 1/20 0.48
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4249744 0.91 ALDH1A1 (0.63) ALDH1A1KDM4EKMT2ALMNARAB9A
SCHEMBL13655416 0.87 GAA (0.62) ALDH1A1KDM4EKMT2ALMNARAB9A
SCHEMBL4256334 0.87 ALDH1A1 (0.61) ALDH1A1KDM4EKMT2ALMNARAB9A
SCHEMBL4252482 0.86 ALDH1A1 (0.71) ALDH1A1KDM4EKMT2ALMNARAB9A
SCHEMBL4249750 0.82 MYB (0.50) KDM4EKMT2ALMNAGAAHTT
SCHEMBL4255026 0.76 KDM4E (0.63) ALDH1A1KDM4EKMT2ALMNAGAA
SCHEMBL4252368 0.75 ALDH1A1 (0.62) ALDH1A1KDM4EKMT2ALMNAGAA
SCHEMBL4256811 0.73 KDM4E (0.62) ALDH1A1KDM4EKMT2ALMNAGAA
SCHEMBL4328201 0.73 TUBB4A (0.57) ALDH1A1KMT2AHSD17B10TUBB4ATUBB
SCHEMBL4252566 0.72 POLB (0.55) ALDH1A1KDM4EKMT2ALMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349864-B2 Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) 2013-01-08 US disclosed
US-8349864-B2 Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) 2013-01-08 US disclosed
US-8349864-B2 Pyrano [3,2-C] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) 2013-01-08 US disclosed
US-20090247566-A1 Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof NEW MEXICO TECHNICAL RESEARCH FOUNDATION 2009-10-01 US disclosed
US-20090247566-A1 Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof NEW MEXICO TECHNICAL RESEARCH FOUNDATION 2009-10-01 US disclosed
US-20090247566-A1 Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof NEW MEXICO TECHNICAL RESEARCH FOUNDATION 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247566-A1 Pyrano [3,2-C] Pyridones and Related Heterocyclic Compounds as Pharmaceutical Agents for Treating Disorders Responsive to Apoptosis, Antiproliferation or Vascular Disruption, and the Use Thereof BAX, CASP3, CASP7 ALDH1A1 1888/4885KDM4E 3525/4885KMT2A 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.